The study, published Saturday in the New England Journal of Medicine, showed how the drug helped people with Type 2 diabetes who also had one of the most common kind of heart failure, obesity-related heart failure with preserved ejection fraction. Obesity-related heart failure with preserved ejection fraction can severely limit a person’s ability to participate in the activities of daily life. Often, people with type 2 diabetes who have this kind of heart failure have a more severe form than those who don’t have diabetes. People with a more severe form of heart failure sometimes don’t respond as well to medication as those with less severe disease. One death in the Wegovy group and four in the placebo group were related to cardiovascular issues.

---

Persons: Wegovy, Ozempic, Dr, Mikhail Kosiborod, “, ” Kosiborod, Naveed Sattar, ” Sattar, Sanjay Gupta, Kosiborod, ” Organizations: CNN, New England, of Medicine, Novo Nordisk –, US Food and Drug Administration, FDA, St, University of Glasgow, Science Media, CNN Health, American College of Cardiology Locations: Asia, Europe, North, South America, Kansas City , Missouri, Atlanta